AVANT DIAGNOSTICS, INC. (OTCMKTS:AVDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

AVANT DIAGNOSTICS, INC. (OTCMKTS:AVDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 9.01 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

On December 4, 2017, Avant Diagnostics,Inc. (the “Company”) accepted the resignation of Philippe Goix as the Company’s chief executive officer and director, effective immediately. There was no disagreement or dispute between Dr. Goix and the Company which led to his resignation.

On December 11, 2017, the Company appointed Scott VanderMeer as the Company’s chief financial officer on an interim basis. Mr. VanderMeer will serve as the Company’s principal executive and principal financial officer. Mr. VanderMeer does not have any family relationship with any director, executive officer or person nominated or chosen by us to become a director or executive officer. There is no understanding or arrangement between Mr. VanderMeer and any other person to which Mr. VanderMeer was selected as an executive officer. Mr. VanderMeer is the founder of Infusion 51a L.P. and International Infusion LP (collectively, the “Investors”), both of whom have participated in private placements in the Company since November 2016. Except as set forth above, there are no transactions in which Mr. VanderMeer has an interest requiring disclosure under Item 404(a) of Regulation S-K. Prior to his appointment as an executive officer, since July 2017, Mr. VanderMeer served as a consultant to the Company. Mr. VanderMeer has been brought on to help facilitate the cleanup of the current balance sheet with legacy AP, assist with the Company’s audit, and work towards up listing the company to a national exchange. Mr. VanderMeer has not entered into any material plan, contract or arrangement in connection with his appointment as an executive officer.

Mr. VanderMeer has been the founder and Managing Partner of Infusion 51a, LP which is a fund that restructures companies with impediments, CFO of VC firm International Infusion LP, and CFO, Founder, and Director of Vivacitas Oncology Inc. an oncology therapeutic company since December 2014, February 2014 and August 2015, respectively. Mr. VanderMeer has been instrumental in the development and expansion of International Infusion’s current portfolio, leveraging key business development relationships, both domestic and international. Mr. VanderMeer has managed the firm’s research committee, focusing on vetting potential projects across an array of sectors. Mr. VanderMeer is responsiblefor activities at each of these entities as they relate to finance, accounting, bookkeeping, working with administrators, corporate communication, and working through audits to completion. Mr. VanderMeer graduated from the University of Illinois at Chicago with a B.S. in Business Marketing and an M.B.A with a concentration in Real Estate.

On December 15, 2017, the Company entered into a Separation and Release Agreement (the “Separation Agreement”) with Philippe Goix, the Company’s former Chief Executive Officer, to which Dr. Goix’s status as chief executive officer and director of the Company ended effective December 4, 2017. to the Agreement, upon the occurrence of a Triggering Event (as defined in the Separation Agreement), the Company shall pay Dr. Goix a lump sum cash payment of $27,346.84 within three (3) business days of the date such Triggering Event occurs. The foregoing information is a summary of the agreement involved in the transaction described above, is not complete, and is qualified in its entirety by reference to the full text of such agreement, a copy of which is attached hereto as Exhibit 10.1. Readers should review such agreements for a complete understanding of the terms and conditions associated with this transaction.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are filed with this report:

Avant Diagnostics, Inc Exhibit
EX-10.1 2 f8k120417ex10-1_avantdiag.htm SETTLEMENT AGREEMENT,…
To view the full exhibit click here


Avant Diagnostics, Inc., formerly American Liberty Petroleum Corp., is a medical diagnostic technology company. The Company focuses on the commercialization of a series of microarray-based diagnostic tests that provide early detection of cancers, neurodegenerative diseases, and other chronic and severe disease states. The Company specializes in large panel biomarker tests. The Company’s lead product is OvaDx, a non-invasive proteomics diagnostic screening test for the early detection of ovarian cancer. The Company’s primary activities are preparing sample specimens in order for OvaDx to obtain the United States Food and Drug Administration (FDA) approval. The Company’s product, OvaDx, is a microarray-based test that measures the activation of the immune system in blood samples in response to early-stage ovarian tumor cell development. It identifies stage I, II, III and IV disease markers in patient samples.

An ad to help with our costs